These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 10374779)
1. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Khoor A; Whitsett JA; Stahlman MT; Olson SJ; Cagle PT Hum Pathol; 1999 Jun; 30(6):695-700. PubMed ID: 10374779 [TBL] [Abstract][Full Text] [Related]
2. TTF-1 and surfactant-B as co-adjuvants in the diagnosis of lung adenocarcinoma and pleural mesothelioma. Bakir K; Koçer NE; Deniz H; Güldür ME Ann Diagn Pathol; 2004 Dec; 8(6):337-41. PubMed ID: 15614737 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. Abutaily AS; Addis BJ; Roche WR J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995 [TBL] [Abstract][Full Text] [Related]
4. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases. Zamecnik J; Kodet R Virchows Arch; 2002 Apr; 440(4):353-61. PubMed ID: 11956814 [TBL] [Abstract][Full Text] [Related]
5. [Surfactant protein and thyroid transcription factor 1 in pleuro-pulmonary neoplasia. Immunohistochemical study]. Dessy E; Falleni M; Del Curto B; Braidotti P; Pietra GG Pathologica; 2000 Dec; 92(6):496-502. PubMed ID: 11234300 [TBL] [Abstract][Full Text] [Related]
6. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Bishop JA; Sharma R; Illei PB Hum Pathol; 2010 Jan; 41(1):20-5. PubMed ID: 19740516 [TBL] [Abstract][Full Text] [Related]
7. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Bejarano PA; Baughman RP; Biddinger PW; Miller MA; Fenoglio-Preiser C; al-Kafaji B; Di Lauro R; Whitsett JA Mod Pathol; 1996 Apr; 9(4):445-52. PubMed ID: 8729987 [TBL] [Abstract][Full Text] [Related]
9. Expression of surfactant protein B precursor and surfactant protein B mRNA in adenocarcinoma of the lung. Khoor A; Whitsett JA; Stahlman MT; Halter SA Mod Pathol; 1997 Jan; 10(1):62-7. PubMed ID: 9021728 [TBL] [Abstract][Full Text] [Related]
10. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Pelosi G; Fraggetta F; Pasini F; Maisonneuve P; Sonzogni A; Iannucci A; Terzi A; Bresaola E; Valduga F; Lupo C; Viale G Am J Surg Pathol; 2001 Mar; 25(3):363-72. PubMed ID: 11224607 [TBL] [Abstract][Full Text] [Related]
11. Ribonucleic Acid In Situ Hybridization Is a More Sensitive Method Than Immunohistochemistry in Detection of Thyroid Transcription Factor 1 and Napsin A Expression in Lung Adenocarcinomas. Shi J; Liu H; Ma XJ; Chen Z; He MX; Luo Y; Lin F Arch Pathol Lab Med; 2016 Apr; 140(4):332-40. PubMed ID: 27028392 [TBL] [Abstract][Full Text] [Related]
12. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Di Loreto C; Puglisi F; Di Lauro V; Damante G; Beltrami CA Cancer Lett; 1998 Feb; 124(1):73-8. PubMed ID: 9500194 [TBL] [Abstract][Full Text] [Related]
13. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983 [TBL] [Abstract][Full Text] [Related]
14. [Use of thyroid transcription factor-1, surfacfant protein-B, cytokeratin 7 and cytokeratin 20 in discrimination between primary and metastatic adenocarcinoma of lung]. Zou SM; Lin DM; Lü N; Liu XY; Wen P; Liu FS Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(15):1350-2. PubMed ID: 12930693 [TBL] [Abstract][Full Text] [Related]
15. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma. Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L Tumori; 2014; 100(5):559-67. PubMed ID: 25343553 [TBL] [Abstract][Full Text] [Related]
16. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Ordóñez NG Am J Surg Pathol; 2000 Apr; 24(4):598-606. PubMed ID: 10757409 [TBL] [Abstract][Full Text] [Related]
17. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468 [TBL] [Abstract][Full Text] [Related]
18. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung. Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids. Afify AM; al-Khafaji BM Acta Cytol; 2002; 46(4):675-8. PubMed ID: 12146029 [TBL] [Abstract][Full Text] [Related]
20. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Kaufmann O; Dietel M Histopathology; 2000 Jan; 36(1):8-16. PubMed ID: 10632746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]